Targeted regulationof STAT3 by miR-29a in mediating Taxol resistance of nasopharyngeal carcinoma cell line CNE-1

Abstract

STAT3 is an important molecule in Janus kinase (JAK) signal transducer and activator of transcription (STAT) signal pathway, and facilitates expression of various oncogenic genes such as Bcl-2, thus is correlated with tumor onset, progression and drug resistance. MiR-29a down-regulation is associated with the pathogenesis of nasopharyngeal carcinoma. Bioinformatics analysis demonstrated a complementary binding between miR-29a and 3’-UTR of STAT3. This study aims to investigate the role of miR-29a in regulating STAT3, as well as in Taxol resistance of nasopharyngeal carcinoma CNE-1 cells. Dual luciferase reporter gene assay showed a regulatory relationship between miR-29a and STAT3. Rhodamine 123 repository in CNE-1 and CNE1/Taxol drug resistant cells was measured together with the expression of miR-29a, STAT3, and p-STAT3. Flow cytometry was used to measure cell apoptosis and PCNA expression under Taxol treatment. CNE-1/Taxol cells were treated with miR-29a mimic and or si-STAT3, followed by measuring the expression of miR-29a, STAT3, and p-STAT3 and cell apoptosis. CCK-8 assay was performed to evaluate cell proliferation. MiR-29a inhibited STAT3 expression. Significantly lower Rhodamine 123 repository, miR-29a expression and apoptosis and higher expression of STAT3, p-STAT3 and PCNA were observed in CNE-2/ Taxol cells than those in CNE-1 cells. Transfection of miR-29a mimic and/or si-STAT3 decreased STAT3, p-STAT3 and PCNA expression, inhibited proliferation and promoted cell apoptosis. MiR-29a down-regulation is correlated with drug resistance of nasopharyngeal carcinoma cell line CNE-1 and MiR-29a up-regulation decreases Taxol resistance of nasopharyngeal carcinoma CNE-1 cells possibly via inhibiting STAT3 and Bcl-2 expression.

Keywords

MiR-29a STAT3 taxol nasopharyngeal carcinoma drug resistance

1. Introduction

Nasopharyngeal carcinoma (NPC) is an epithelial derived malignant tumor which is frequently occurred in nasopharyngeal cavity upper and lateral walls. As a common malignant tumor in Southeastern Asia and Southern China, NPC has a relatively higher incidence [1]. Currently, radiotherapy is often used to treat NPC in clinic. Combined chemotherapy helps to improve treatment efficacy and prognosis for those NPC patients with recurrence or metastasis. However, some patients present drug resistance for chemotherapy drugs, mainly contributing to the failure of chemotherapy and mortality [2].

In Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signal transduction pathway, STAT protein family consists of 7 members, in which STAT3 and STAT5 are closely associated with human tumor pathogenesis, especially for STAT3 [3]. Potential expression and activity of STAT3 is closely correlated with the onset, progression, invasion and metastasis of breast cancer [4], colon cancer [5] and gastric carcinoma [6], and affects patient survival and prognosis. The role of STAT3 in chemotherapy resistance of lung cancer [7], lymphoma [8] and prostate cancer [9] has also been reported.

MicroRNA is a family of endogenous non-coding small molecular single stranded RNA with a length of 22 $\sim$ 25 nucleic acids in eukaryotes. It can regulate target gene expression via complementary binding to the 3’-UTR of target gene mRNA leading to degradation or translational inhibition, playing an important role in tumor occurrence [10]. Previous study showed significantly lowered miR-29a expression in NPC tumor tissues [11] and peripheral blood [12], which is associated with clinical features and prognosis, indicating a possible tumor suppression role in NPC. Moreover, various studies showed an important role of miR-29a in mediating tumor cell drug resistance [13, 14]. Bioinformatics showed a complementary binding relationship between miR-29a and 3’-UTR or STAT3 mRNA. Taxol is a common chemotherapy drug and drug resistance severely limits the treatment efficacy. Therefore, this study established Taxol-resistant cell model by drug induction, to investigate whether miR-29a regulated STAT3 expression and affected Taxol resistance of NPC.

2. Materials and methods

2.1 Major reagents and materials

Human NPC cell line CNE-1 and immortalized nasopharyngeal epithelial cell line NP69 were purchased from Xinyu Biotech (Zhangjiakou, Hebei, China). DMEM and 1640 medium, streptomycin-penicillin and fetal bovine serum (FBS) were purchased from Gibco BRL. Co. Ltd. (Grand Island, NY, USA). RNA extraction kit Rneasy MiNi Kit was purchased from Qiagen (Hilden, Germany). FuGENE HD Transfection Reagent was purchased from Roche Pharma (Basel, Switzerland). PrimerScript™ RT reagent Kit and SYBR Green dye were purchased from Takara (Dalian, Liaoning, China). MiR-29a mimic and miR-NC were synthesized by Ruibo Bio. Technol. Co. Ltd. (Guangzhou, Guangdong, China). Mouse anti-human STAT3, p-STAT3, Bcl-2 and $\beta$ -actin monoclonal antibody were purchased from GeneTex Inc. (Irvine, CA, USA). HRP conjugated rabbit anti-mouse secondary antibody was purchased from Xinbo Biotech (Suzhou, Jiangshu, China). Taxol was purchased from Huasu Pharma (Beijing, China). Proliferating cell nuclear antigen (PCNA) antibody with PECy5 labels was purchased from Ambion (Austin, TX, USA). Rhodamine 123 was purchased from Amresco Inc. (Solon, OH, USA). Luciferase gene repoter plasmid pLUC Luciferase vector was purchased from Ambion (Austin, TX, USA). APC labelled proliferating cell nuclear antigen (PCNA) antibody was purchased from Biolegend (San Diego, CA, USA). Dual luciferase activity assay kit was purchased from Promega (Madison, MI, USA). RIPA lysis buffer, BCA protein quantification kit, and cell apoptotic kit were purchased from Beyotime Biotech (Shanghai, China). CCK-8 assay kit was purchased from Toyobo Co. Ltd. (Osaka, Japan).

2.2 Cell culture

CNE-1 and NP69 cells were cultured in 1640 medium containing 10% FBS and 1% streptomycin in a 37 ${}^{\circ}$ C incubator with 5% CO ${}_{2}$ . Cells at log-growth phase were used for experiments.

2.3 Establishment of CNE-1/Taxol model and drug resistance index

CNE-1/Taxol cell line was established by gradient induction. In brief, cells at log-growth phase were treated with 0.1 $\mu$ g/l Taxol. Twenty-four hours later, Taxol was removed and cells were washed by PBS. When cells’ status returned to normal growth, they were passed for three generations followed by gradually increasing the concentration of Taxol to 0.2, 0.5, 1.0 and 2.0 $\mu$ g/l until CNE-1 cells can maintain normal growth status with repeated passage. Those cells that can normally grow under the treatment of 2.0 $\mu$ g/l Taxol were named as CNE-1/Taxol.

CNE-1/Taxol and CNE-1 cells were treated with 0, 0.25, 0.5, 1, 2.5, 5, 10, and 20 $\mu$ g/l Taxol. Six replicates were performed for each concentration. After 48 h incubation, CCK-8 assay was performed to calculate the absorbance value (A450) of each well. Inhibition rate (%) $=$ (1 $-$ A450 of drug treatment group)/A450 of control group $\times$ 100%. IC ${}_{50}$ value was calculated as the drug concentration required for inhibiting 50% cell growth. Resistance index (RI) $=$ IC ${}_{50}$ of CNE-1/Taxol cells/IC ${}_{50}$ of CNE-1 cells.

2.4 Measurement of PCNA expression

CNE-1/Taxol and CNE-1 cells were cultured in Taxol with IC ${}_{50}$ concentration of CNE-1 cells. Forty-eight hours later, cells were collected and digested by trypsin. Two point five $\mu$ l PECy5-PCNA was added into cell suspensions and incubated under dark incubation at 4 ${}^{\circ}$ C for 30 min, followed by measuring PCNA expression by flow cytometry to evaluate cell proliferation under Taxol treatment.

2.5 Rhodamine 123 refusal staining assay

CNE-1/Taxol and CNE-1 cells were re-suspended in 1640 medium containing 0.1% Rhodamine solution. After incubation at 37 ${}^{\circ}$ C for 15 min, cells were rinsed in 1640 medium for three times, and re-suspended in 1640 medium. After 37 ${}^{\circ}$ C continuous incubation for 60 min, cells were rinsed for three times using 1640 medium. Cell suspensions were prepared for smear slide, which were observed under a fluorescent microscope (Mode: IX51, Olympus, Tokyo, Janan) for cell staining.

2.6 Dual luciferase activity assay

Full length or mutant fragment of 3’-UTR of STAT3 gene was amplified by PCR, digested by SacI and XbaI endo-nuclease, and sub-cloned into pLUC dual luciferase gene reporter plasmid, which was named as pLUC-STAT3-wt. Luciferase reporter vector containing mutant form of the 3’-UTR of STAT3 gene was also constructed as pLUC-STAT3-mut. FuGENE HD Transfection Reagent was used to transfect pLUC-STAT3-wt (or pLUC-STAT3-mut) and miR-29a mimic into HEK293T cells. After 48 h, dual luciferase activity was measured by a commercial kit according to the manufacturer’s instructions.

2.7 Cell transfection and grouping

In vitro cultured CNE-1/Taxol cells were divided into five groups: miR-NC transfection group, miR-29a mimic transfection group, si-NC transfection group; si-STAT3 group, and miR-29a mimic $+$ si-STAT3 group. Seventy-two hours after transfection, cells were collected for measuring gene and protein expression to substantiate efficacy of over-expression and interference. Transfected cells from all groups were treated with 2.0 $\mu$ g/l Taxol for 48 h and cell apoptosis was measured by flow cytometry.

2.8 qRT-PCR for gene expression

PrimeScript™ RT reagent kit was used to synthesize cDNA by reverse transcription using RNA which was extracted using Rneasy MiNi Kit. Using cDNA as the template, PCR amplification was performed. Primer sequences were designed as follows: miR-29aP ${}_{\text{F}}$ : 5’-G CCCTAGCACCATCTGAAAT-3’; miR-29aP ${}_{\text{R}}$ : 5’-GT GCAGGGTCCGAGGT-3’; U6P ${}_{\text{F}}$ : 5’-ATTGGAACG ATACAGAGAAGATT-3’; U6P ${}_{\text{R}}$ : 5’-GGAACGCTTC ACGAATTTG-3’; STAT3P ${}_{\text{F}}$ : 5’-ATCACGCCTTCTA CAGACTGC-3’; STAT3P ${}_{\text{R}}$ : 5’-CATCCTGGAGATTC TCTACCACT-3’; Bcl-2P ${}_{\text{F}}$ : 5’-GGTGGGGTCATGTG TGTGG-3’; Bcl-2P ${}_{\text{R}}$ : 5’-CGGTTCAGGTACTCAGT CATCC-3’; $\beta$ -actinP ${}_{\text{F}}$ : 5’-GAACCCTAAGGCCAAC-3’; $\beta$ -actinP ${}_{\text{R}}$ : 5’-TGTCACGCACGATTTCC-3’. PCR was performed on ABI ViiA™ 7 fluorescent quantitative PCR cycler with conditions as follows: 95 ${}^{\circ}$ C pre-denature for 15 min, followed by 40 cycles of 94 ${}^{\circ}$ C denature for 15 s, 60 ${}^{\circ}$ C annealing for 30 s, and 72 ${}^{\circ}$ C elongation for 30 s.

2.9 Western blot

RIPA lysis buffer was used to extract protein, followed by examination of the quality and concentration. Forty $\mu$ g proteins were separated in 10% SDS-PAGE and transferred to PVDF membrane, which was blocked with 5% defatted milk powder at room temperature. Primary antibody (STAT3 at 1: 300, p-STAT3 at 1: 100, Bcl-2 at 1: 300, $\beta$ -actin at 1: 800) was added and incubated at 4 ${}^{\circ}$ C overnight. After PBST rinsing, HRP conjugated-secondary antibody (1: 8000 dilution) was added for 60 min incubation. The membrane was rinsed in PBST and quantified for protein expression using ECL reagent.

2.10 Analysis of cell apoptosis

Cells were collected and digested by trypsin, and re-suspended in Binding Buffer. Five $\mu$ l Annexin V-FITC and 5 $\mu$ l PI staining buffer were sequentially added into cells followed by measuring cell apoptosis by Beckman Coulter Gallios flow cytometry (Mode: FC500, Beckman, Germany).

2.11 Cell proliferation analysis

Cells from all groups were cultured in 1640 medium containing 2.0 $\mu$ g/l Taxol for 24 h, 48 h, 72 h, 96 h and 120 h, followed by measuring cell proliferation using CCK-8 assay kit.

2.12 Statistical analysis

SPSS18.0 was used for data analysis. Measurement data were presented as mean $\pm$ standard deviation (SD). Student t-test was used for comparing measurement data between groups. A statistical significance was defined when $p<$ 0.05.

3. Results

3.1 MiR-29a inhibits STAT3 expression

Bioinformatics analysis showed a complementary binding relationship between miR-29a and the 3’-UTR of STAT3 mRNA (Fig. 1A). Dual luciferase gene reporter assay showed that transfection of miR-29a mimic significantly decreased the relative luciferase activity in HEK293T cells (Fig. 1B), indicating that miR-29a targeted the 3’-UTR of STAT3 mRNA to suppress its expression.

Figure 1.

MiR-29a inhibited STAT3 expression. (A) Binding sites between miR-29a and 3’-UTR of STAT3 mRNA; (B) Dual luciferase gene reporter assay. *, $p<$ 0.05 comparing miR-29a mimic and miR-NC.

3.2 MiR-29a down-regulation is correlated with CNE-1 cell drug resistance

qRT-PCR analysis showed significantly lower miR-29a expression in CNE-1 cells compared to NP96 cells, whilst STAT3 mRNA level was elevated (Fig. 2A). Comparing to CNE-1 cells, CNE-1/Taxol cells had significantly lower miR-29a expression and higher STAT3 mRNA expression (Fig. 2A). Consistently, western blot analysis showed significantly increased STAT3 and p-STAT3 expression in CNE-1/Taxol cells compared to those in CNE-1 cells, which had higher STAT3 and p-STAT3 expression than NP96 cells (Fig. 2B). Rhodamine 123 repository assay showed more dyes in CNE-1 cells and lower repository in CNE-1/Taxol cells, indicating refusal of staining (Fig. 2C). Flow cytometry demonstrated that under the treatment of equal concentration of Taxol, CNE-1/Taxol cells had higher PCNA expression than CNE-1 cells (Fig. 2D), but with lower cell apoptotic rate (Fig. 2E).

3.3 MiR-29a up-regulation and STAT3 down-regulation reduces drug resistance of CNE-1/Taxol cells

Next, we investigated the changes of drug resistance in CNE-1/Taxol cells with miR-29a up-regulation and/or STAT3 down-regulation under the treatment of 2.0 $\mu$ g/L Taxol. Results showed that transfection of miR-29a mimic and/or si-STAT3 significantly decreased the expression of STAT3, p-STAT3 and Bcl-2 in CNE-1/Taxol cells (Fig. 3A and B), inhibited cell proliferation (Fig. 3C), and promoted cell apoptosis (Fig. 3D).

Figure 2.

MiR-29a down-regulation was involved in CNE-1 cell drug resistance. (A) qRT-PCR for gene expression; (B) Western blot for protein expression; (C) Rhodamine 123 refusal staining assay; (D) Flow cytometry for PCNA expression; (E) Flow cytometry for cell apoptosis. *, $p<$ 0.05 comparing between CNE-1 cells and NP96 cells; #, $p<$ 0.05 comparing between CEN-1/Taxol cells and Taxol cells.

Figure 3.

MiR-29a up-regulation and STAT3 down-regulation reduced drug resistance of CNE-1/Taxol cells. (A) qRT-PCR for gene expression; (B) Western blot for protein expression; (C) CCK-8 assay for cell proliferation activity; (D) Flow cytometry for cell apoptosis. a, $p<$ 0.05 comparing between miR-29a mimic and miR-NC; b, $p<$ 0.05 comparing between si-NC and si-STAT3; c, $p<$ 0.05 comparing between miR-29a mimic $+$ si-STAT3 and miR-29a mimic; d, $p<$ 0.05 comparing between miR-29a mimic $+$ si-STAT3 and si-STAT3.

4. Discussion

JAK-STAT signal pathway integrates multiple extra-cellular signal pathways including cytokines, growth factor and mitogen, and plays an important role in regulating cell growth, mitosis, proliferation or apoptosis [3]. STAT transcription factor protein family consists of 7 members, in which STAT3 and STAT5 are closely associated with human tumor occurrence, especially for STAT3. Under the activation of JAK-STAT3 signal pathway, dimerization of membrane receptor can phosphorylate JAK kinase, which then phosphorylates the receptor, leading to recruitment of STAT3 onto the membrane receptor and subsequent phosphorylation of STAT3 under JAK direction. Phosphorylated and activated STAT3 detaches from the receptor, resulting in dimerization and subsequent transportation from cytoplasm into the nucleus, where it exerts functions on specific DNA fragment to mediate gene expression. Enhanced cytoplasm and activity of STAT3 can potentiate transcription and expression of various oncogenic-like genes including Bcl-2, Bcl-xl, and is closely associated with the onset, progression, invasion and metastasis of multiple tumors including breast cancer [4], colon cancer [5] and gastric carcinoma [6], leading to shortened overall survival and poor prognosis. Moreover, elevated expression and activity of STAT3 is also an important factor endowing drug resistance for tumor cells [9].

Recently, a study illustrated the close correlation between miR-29a down-regulation and the occurrence, progression and prognosis of NPC [11, 12]. In addition, various studies have indicated critical roles of miR-29a expression in mediating drug resistance of tumor cells [13, 14]. Bioinformatics analysis revealed a complementary binding association between miR-29a and 3’-UTR of STAT3 mRNA, indicating a possible regulatory relationship. Taxol is a tetracyclic diterpene compound extracted from Taxus brevifolia. As a cell cycle specific drug, it can inhibit denature of micro-tubulin and spindle fiber formation during mitosis, thus suppressing cell proliferation and facilitating apoptosis. As a cytotoxic drug, Taxol has been used for treating various tumors including ovarian cancer [15], esophageal squamous carcinoma [16] and breast cancer [17]. Therefore, this study established a Taxol-resistant cell model by drug induction, to investigate the role of miR-29a in mediating STAT3 expression as well as in Taxol drug resistance of NPC.

In this study, we showed that compared to NP96 cells, miR-29a expression in NPC cell line CNE-1 was significantly decreased, accompanied with elevated STAT3 and p-STAT3 expression, indicating that NPC cells had potentiated phosphorylation of STAT3, plus it up-regulation, in which miR-29a down-regulation might play a role in enhancing STAT3 and p-STAT3 expression as well as in facilitating NPC pathogenesis. Rhodamine 123 staining showed more repository in CNE-1 cells compared to CNE-1/Taxol cells, suggesting drug resistant mechanism involving exclusion of drugs. In addition, IC50 value of CNE-1/Taxol cells (14.57 $\mu$ g/l) was significantly higher than that of CNE-1 cells (1.22 $\mu$ g/l), with RI $=$ 11.94. Comparing to CNE-1 cells, CNE-1/Taxol cells had significantly elevated expression of STAT3 and p-STAT3, but miR-29a expression was decreased. These results showed the role of miR-29a down-regulation in inducing Taxol drug resistance, in addition to NPC pathogenesis. Luo et al. [11] performed a gene micro-array screening and found significantly lowered miR-29a expression in NPC tumor tissues compared to normal healthy nasopharyngeal epithelium. With advanced clinical stage, its expression level was further down-regulated, and reached a minimal level in patients with distal metastasis. Wang et al. showed significantly decreased miR-29a expression in peripheral blood samples in NPC patients, and lower 5-year survival rate in patients with miR-29a down-regulation compared to those with higher levels (54.8% vs 82.8%) [12]. In this study, miR-29a expression was significantly lower in NPC cell line compared to normal nasopharyngeal epithelium, indicating a possible role of miR-29a down-regulation in NPC pathogenesis, which was consistent with studies conducted by Luo et al. [11] and Wang et al. [12]. Xu et al. showed significantly higher expression and phosphorylated level of STAT3 in NPC cell line C666-1 [18]. In this study, the expression of STAT3 and p-STAT3 in NPC cells was significantly higher than NP69 cells, which was in accordance with Xu et al. [18]. Regarding the association between miR-29a and chemotherapy sensitivity, Moussay et al. found that chronic lymphoma patients with fludarabine-resistance had lower miR-29a in peripheral blood compared to those patients with drug sensitivity [19]. Yu et al. showed lower miR-29a expression in cisplatin-induced drug resistant cell line of ovarian cancer [14], further indicating involvement of miR-29a down-regulation in tumor cell drug resistance. These studies all revealed the role of miR-29a down-regulation in facilitating tumor cell resistance, which was consistent with our study. Further investigations showed that transfection of miR-29a mimic and/or si-STAT3 remarkably inhibited STAT3 and p-STAT3 expression in CNE-1/Taxol cells, and suppressed stable growth under the treatment of 2.0 $\mu$ g/L Taxol, whilst increased apoptosis. Yu et al. showed that inhibition of miR-29a expression significantly enhanced cisplatin resistance in ovarian cancer cells, whilst miR-29a over-expression facilitated ovarian cancer cell death under cisplatin treatment and enhanced drug sensitivity of cancer cells [14].

In this study, up-regulation of miR-29a inhibited drug resistance of tumor cells, consistent with Yu et al. [14]. Xu et al. showed significantly reduced NPC C666-1 cell proliferation, migration and invasion after STAT3 inhibition, plus potentiated cell apoptosis [18]. Tsang et al. showed that after drug intervention on STAT3 activity, in vitro proliferation potency and in vivo tumor genesis of NPC C666-1 cells were remarkably inhibited, but cell apoptosis was elevated [20]. Pan et al. found that after blocking STAT3 activity using small molecule inhibitor Static, NPC cell proliferation was inhibited, with increased apoptosis and sensitivity for chemotherapy drug cisplatin [21]. This study found that suppression of STAT3 expression or function could inhibit malignant biological properties of NPC including proliferation and apoptosis, and enhance chemotherapy drug sensitivity, as supported by Xu et al. [18], Tsang et al. [20] and Pan et al. [21]. This study revealed the role of miR-29a down-regulation in up-regulating STAT3 expression or function, as well as in enhancing drug resistance of NPC cells.

There are some limitations in the present study. Firstly, the other NPC cells with low expression of miR-29a and high expression of STAT3 have not been investigated in this study, which should be investigated in further studies to provide more constructive conclusion regarding the role of miR-29a and STAT3 in the pathogenesis of NPC. Secondly, the present study only knockdown the STAT3 gene by siRNA, however, the effects of siRNA mediated gene knockdown is temporary [22]. Therefore, knockout of STAT3 should be performed in the following study to confirm the role of STAT3. Thirdly, as almost all cells in the in vivo environment are surrounded by other cells and extracellular matrix in a three-dimensional (3D) fashion, 2D cell culture does not adequately mimic the natural 3D environment of cells. The 2D cell culture used in the present study might provide misleading and nonpredictive data forin vivo responses [23, 24]. Therefore, 3D spheroids or the xenografts would be required in the future.

5. Conclusion

MiR-29a down-regulation is correlated with NPC cell line CNE-1 drug resistance. Up-regulation of miR-29a decreases Taxol drug resistance of CNE-1 cells possibly via inhibition of STAT3 and Bcl-2 expression.

Footnotes

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 81472988).

Conflict of interest

None.

References

Zhang

Chen

Liang

and Zheng

, The best combination treatment of patients with advanced nasopharyngeal carcinoma, J Clin Oncol 29 (2011), e16018.

Chen

C.Y.

Lin

Y.S.

Chen

C.L.

Chao

P.Z.

Chiou

J.F.

Kuo

C.C.

Lee

F.P.

Lin

Y.F.

Sung

Y.H.

Lin

Y.T.

C.F.

Chen

Y.J.

and Chen

C.H.

, Targeting annexin A2 reduces tumorigenesis and therapeutic resistance of nasopharyngeal carcinoma, Oncotarget 6 (2015), 26946–59.

Swierkot

Nowak

Czarny

Zaczynska

Sokolik

Madej

Korman

Sebastian

Wojtala

Lubinski

and Wiland

, The activity of JAK/STAT and NF-kappaB in patients with rheumatoid arthritis, Adv Clin Exp Med 25 (2016), 709–17.

Liu

Zhang

and Song

, Upregulation of MEK5 by Stat3 promotes breast cancer cell invasion and metastasis Oncol Rep 37 (2017), 83–90.

Berthenet

Bokhari

Lagrange

Marcion

Boudesco

Causse

De Thonel

Svrcek

Goloudina

A.R.

Dumont

Hammann

Biard

D.S.

Demidov

O.N.

Seigneuric

Duval

Collura

Jego

and Garrido

, HSP110 promotes colorectal cancer growth through STAT3 activation, Oncogene (2016).

Shen

Yuan

Zhao

Lou

Zheng

Guo

and Xi

, Novel long non-coding RNA GACAT3 promotes gastric cancer cell proliferation through the IL-6/STAT3 signaling pathway, Tumour Biol 37 (2016), 14895–14902.

Cuyas

Perez-Sanchez

Micol

Menendez

J.A.

and Bosch-Barrera

, STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer, Cell Cycle 15 (2016), 3413–3418.

Jiang

Liu

Tang

Zeng

and Zhong

, ALDH1A1 induces resistance to CHOP in diffuse large B-cell lymphoma through activation of the JAK2/STAT3 pathway, Biochem Biophys Res Commun (2016).

Tang

Marquez

R.T.

Highfill

C.A.

Lian

Lin

Fuchs

J.R.

and Xu

, Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling, Oncotarget 7 (2016), 11708–23.

10.

Wang

Liu

Zhang

Wang

Zhang

Dong

Wang

Xue

Yang

Tan

Wang

and Song

, miR-942 promotes cancer stem cell-like traits in esophageal squamous cell carcinoma through activation of Wnt/beta-catenin signalling pathway, Oncotarget 6 (2015), 10964–77.

11.

Luo

Zhang

Jiang

Dai

Guo

Xiang

and Li

, An in silico analysis of dynamic changes in microRNA expression profiles in stepwise development of nasopharyngeal carcinoma, BMC Med Genomics 5 (2012), 3.

12.

Wang

H.Y.

Yan

L.X.

Shao

Zhang

Z.C.

Zeng

Y.X.

and Shao

J.Y.

, Profiling plasma microRNA in nasopharyngeal carcinoma with deep sequencing, Clin Chem 60 (2014), 773–82.

13.

Shen

Yang

Wang

Zhong

Zhao

and Tang

, MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3beta signaling pathway, Gene 593 (2016), 84–90.

14.

P.N.

Yan

M.D.

Lai

H.C.

Huang

R.L.

Chou

Y.C.

Lin

W.C.

Yeh

L.T.

and Lin

Y.W.

, Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells, Int J Cancer 134 (2014), 542–51.

15.

Yuan

Sheng

Clark

L.H.

Zhang

Guo

Jones

H.M.

Willson

A.K.

Gehrig

P.A.

Zhou

and Bae-Jump

V.L.

, Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer, Am J Transl Res 8 (2016), 4265–4277.

16.

Liu

Ren

Yuan

Yao

Qiao

and Li

, Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer, Am J Cancer Res 6 (2016), 2345–2350.

17.

Peng

Yan

Yang

Qiao

and Liu

, Neutralization of TNFalpha in tumor with a novel nanobody potentiates paclitaxel-therapy and inhibits metastasis in breast cancer, Cancer Lett 386 (2017), 24–34.

18.

Zhao

Hui

Song

Miao

Z.W.

and Jiang

X.J.

, MicroRNA-124-3p inhibits the growth and metastasis of nasopharyngeal carcinoma cells by targeting STAT3, Oncol Rep 35 (2016), 1385–94.

19.

Moussay

Palissot

Vallar

Poirel

H.A.

Wenner

El Khoury

Aouali

Van Moer

Leners

Bernardin

Muller

Cornillet-Lefebvre

Delmer

Duhem

Ries

van Dyck

and Berchem

, Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia, Mol Cancer 9 (2010), 115.

20.

Tsang

C.M.

Cheung

Y.C.

Lui

V.W.

Yip

Y.L.

Zhang

Lin

V.W.

Cheung

K.C.

Feng

and Tsao

S.W.

, Berberine suppresses tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation induced by tumor associated fibroblasts, BMC Cancer 13 (2013), 619.

21.

Pan

Zhou

Zhang

and Claret

F.X.

, Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma, PLoS One 8 (2013), e54565.

22.

Harborth

Elbashir

S.M.

Bechert

Tuschl

and Weber

, Identification of essential genes in cultured mammalian cells using small interfering RNAs, J Cell Sci 114 (2001), 4557–65.

23.

Birgersdotter

Sandberg

and Ernberg

, Gene expression perturbation in vitroa growing case for three-dimensional (3D) culture systems, Semin Cancer Biol 15 (2005), 40512.

24.

Bhadriraju

and Chen

C.S.

, Engineering cellular microenvironments to improve cell-based drug testing, Drug Discov Today 7 (2002), 61220.